{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:35:45Z","timestamp":1776108945491,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Ganciclovir and valganciclovir are first-line treatments for cytomegalovirus in immunocompromised children; however, the optimal therapeutic target remains unclear. This review identified 6 studies that showed clearance of cytomegalovirus viremia occurs with a median area under the concentration\u2013time curve (AUC<jats:sub>24<\/jats:sub>) between 23 and 70 \u03bcg\u00b7h\/mL, with no clear correlation with efficacy or toxicity.<\/jats:p>","DOI":"10.1097\/inf.0000000000004602","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T20:00:16Z","timestamp":1730491216000},"page":"326-329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Defining a Therapeutic Target for Ganciclovir Therapy in Immunocompromised Children With Cytomegalovirus Infection: A Brief Report"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0407-9339","authenticated-orcid":false,"given":"Maggie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Weerdenburg","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"The Royal Children\u2019s Hospital, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China"},{"name":"Department of Pharmacy, Minhang Hospital, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Gwee","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"The Royal Children\u2019s Hospital, Melbourne, Victoria, Australia"},{"name":"Antimicrobial Group, Murdoch Children\u2019s Research Institute, Melbourne, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host.","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/petr.12030","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.","volume":"17","author":"Villeneuve","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/INF.0b013e3182463a19","article-title":"Pharmacokinetic profile of valganciclovir in pediatric transplant recipients.","volume":"31","author":"Launay","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"Art no. 614164","DOI":"10.3389\/fphar.2020.614164","article-title":"Population pharmacokinetics and dose optimization of ganciclovir in critically ill children.","volume":"11","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1086\/317600","article-title":"Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects.","volume":"182","author":"Frenkel","year":"2000","journal-title":"J Infect Dis"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00467-003-1226-x","article-title":"Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.","volume":"18","author":"Zhang","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/psp4.12363","article-title":"Pediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure.","volume":"8","author":"Jorga","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/antibiotics10010077","article-title":"Valganciclovir-ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship.","volume":"10","author":"Galar","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study.","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1111\/bcp.14719","article-title":"Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.","volume":"87","author":"Franck","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1086\/515281","article-title":"Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy.","volume":"177","author":"Macdonald","year":"1998","journal-title":"J Infect Dis"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/AAC.02130-15","article-title":"Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients.","volume":"60","author":"Padull\u00e9s","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:00:32Z","timestamp":1749502832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004602","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}